Braxia buys KetaMD to get into remote-delivered ketamine treatments
Braxia Scientific is a Toronto-based company that focuses on depression, suicidality and related mental health conditions. Today, the company announced it is buying KetaMD to extend its telehealth prowess and in particular to expand its tech-facilitated ketamine-based treatments from its current local market of Florida into the wider U.S. The deal is worth around $6 … Continue reading Braxia buys KetaMD to get into remote-delivered ketamine treatments
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed